Related Experiment Video
Updated: Feb 7, 2026

An In Vitro Model for Studying Cellular Transformation by Kaposi Sarcoma Herpesvirus
Published on: August 25, 2017
Response to Checkpoint Inhibitor Therapy in Advanced Classic Kaposi Sarcoma: A Case Report and Immunogenomic Study
Abstract:
Kaposi sarcoma (KS) is an uncommon angioproliferative malignancy that is associated with human herpesvirus 8. Although there has been recent enthusiasm for evaluating immune checkpoint inhibition as a therapeutic option for viral-associated tumors, the clinical utility in this disease is currently unknown. We report a case of advanced classic KS refractory to multiple lines of chemotherapy that experienced a partial response to anti-PD-1 therapy. Comprehensive molecular profiling was performed on a diagnostic tumor biopsy sample. Molecular profiling data from 8 additional male patients with KS were reviewed and compared with those of the index case. The genomic profile of the index case was notable for higher-than-typical somatic mutational burden, including pathogenic mutation in multiple well-described cancer genes, such as TP53, CDKN2A, NOTCH1, and KRAS Our case suggests that further clinical study of checkpoint inhibitor therapy in classic KS is warranted, and provides a hypothesis for future immunogenomic biomarker analysis in this disease.
Insights
Advanced classic Kaposi sarcoma (KS), a rare cancer linked to human herpesvirus 8, showed partial response to anti-PD-1 therapy. This suggests immune checkpoint inhibitors may benefit KS patients.
Area of Science:
- Oncology
- Immunology
- Genomics
Background:
- Kaposi sarcoma (KS) is an uncommon angioproliferative malignancy associated with human herpesvirus 8.
- Immune checkpoint inhibition is a promising therapeutic strategy for viral-associated tumors, but its utility in KS is not yet established.
Observation:
- A case of advanced classic KS, resistant to chemotherapy, demonstrated a partial response to anti-PD-1 therapy.
- Comprehensive molecular profiling of the KS tumor revealed a high somatic mutational burden, including mutations in TP53, CDKN2A, NOTCH1, and KRAS.
Findings:
- The genomic profile of the index case showed a higher-than-typical somatic mutational burden.
- Comparison with 8 additional male KS patients' molecular data was performed.
Implications:
- This case suggests that further clinical investigation of immune checkpoint inhibitor therapy in classic KS is warranted.
- The findings provide a hypothesis for future immunogenomic biomarker analysis in Kaposi sarcoma.
Related Concept Videos
The Spindle Assembly Checkpoint
Many proteins function together to control the spindle assembly checkpoint. Mutations affecting these proteins may allow cells to proceed into anaphase prematurely, resulting in the...
Classical Conditioning
Ivan Pavlov observed that dogs...
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Data Reporting and Recording
Principles of Classical Conditioning
During the...
Classical Conditioning in Daily Life
John B. Watson and Rosalie Rayner famously demonstrated the development of fear through classical conditioning in their experiment with Little Albert. They paired the...

